Author's response to reviews

Title: Study protocol of the TRICOLORE trial: A randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer

Authors:

Yoshito Komatsu (ykomatsu@ac.cyberhome.ne.jp)
Chikashi Ishioka (chikashi@idac.tohoku.ac.jp)
Ken Shimada (shimakenken60@hotmail.com)
Yasuhide Yamada (yayamada@ncc.go.jp)
Makio Gamoh (m.gamoh-oc@h-osaki.jp)
Atushi Sato (sato1151@cc.hirosaki-u.ac.jp)
Tatsuro Yamaguchi (tatsuro@yamaguchi.email.ne.jp)
Satoshi Yuki (satoshi-yuuki175@joy.ocn.ne.jp)
Satoshi Morita (smorita@kuhp.kyoto-u.ac.jp)
Shin Takahashi (swt@idac.tohoku.ac.jp)
Rei Goto (goto.rei.7w@kyoto-u.ac.jp)
Minoru Kurihara (kurihara@tcog.jp)

Version: 3
Date: 27 July 2014

Author's response to reviews: see over
Professor Dafne Solera  
Executive Editor  
*BMC Cancer*

Dear Professor Solera;

On behalf of all the authors, I would like to ask you to consider our manuscript entitled "Study protocol of the TRICOLORE trial: A randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer" for publication in *BMC Cancer* as a study protocol article.

This randomized phase III study evaluates efficacy, adverse events, quality of life, and medical costs of S-1 containing irinotecan-based regimen comparing to those of oxaliplatin-based regimen. Correlations of efficacy with relevant biomarkers are also investigated.

All study participants are supposed to provide informed consent after approval of the ethics review board of each institution.

We feel that this study design will be of special interest to the readers of *BMC Cancer*.

This manuscript has not been published and is not under consideration for publication elsewhere. All the authors have read the manuscript and have approved this submission.

This study is being conducted “The Tokyo Cooperative Oncology Group” with funding from Taiho Pharmaceutical Co. Ltd., Japan under study contract. The authors reported competing interest in the manuscript.

Sincerely,

Yoshito Komatsu, M.D., Ph.D.  
Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center  
North 15, West 7, Kita-ku, Sapporo 060-8638, Japan.  
TEL: +81-11-706-5657  
FAX: +81-11-706-5657  
E-mail: ykomatsu@ac.cyberhome.ne.jp